Spectroscopic analysis

• US 9,625,377 B2
• Filed: 02/29/2016
• Issued: 04/18/2017
• Est. Priority Date: 04/06/2011
• Status: Active Grant

• Current Assignee: Klein Medical Ltd.
• Original Assignee: Klein Medical Ltd.
• Inventors: Smith, Bryan James, Krouse, Donal Paul, Simpkin, Raymond Andrew
• Primary Examiner(s): STAFIRA, MICHAEL PATRICK
• Application Number:
  US15/056,907
• Publication Number:
  US 20160320295A1
• Time in Patent Office: 414 Days
• CPC Class Codes: G01J 2003/1286 Polychromator in general
• CPC Class Codes: G01J 3/10 Arrangements of light sources specially adapted for spectrometry or colorimetry
• CPC Class Codes: G01J 3/28 Investigating the spectrum using colour filters G01J3/51
• CPC Class Codes: G01J 3/42 Absorption spectrometry; Double beam spectrometry; Flicker spectrometry; Reflection spectrometry beam switching arrangements G01J3/08
• CPC Class Codes: G01N 2021/3595 using FTIR
• CPC Class Codes: G01N 21/3577 for analysing liquids, e.g. polluted water
• CPC Class Codes: G01N 21/359 using near infrared light
• CPC Class Codes: G01N 21/84 Systems specially adapted for particular applications
• CPC Class Codes: G01N 2201/0612 Laser diodes
• CPC Class Codes: G01N 2201/0691 Modulated (not pulsed supply)

Abstract

An analyser and related methods for characterising a sample. The analyser includes an integrated laser for emitting electromagnetic radiation in at least one beam at a sample. The electromagnetic radiation can include at least two different wavelengths. A sample detector detects affected electromagnetic radiation resulting from the emitted electromagnetic radiation affected by the sample and provides output representing the detected affected radiation. The analyser also includes a processor for characterising the sample from the detector output representing the detected affected electromagnetic radiation.

Claims

1. An analyser for identifying or verifying a liquid drug comprising a drug in a base liquid, the liquid drug having a liquid drug spectrum and the base liquid having a base liquid spectrum comprising at least one spectral characteristic feature between about 1300 nm and about 2000 nm, the analyser comprising:

an integrated laser for emitting electromagnetic radiation at a liquid drug, the electromagnetic radiation comprising a plurality of different wavelengths spread across about 1300 nm to about 2000 nm, wherein at least one of the wavelengths is in the vicinity of or within a region spanning a wavelength of a spectral characteristic feature of the base liquid spectrum, the integrated laser comprising;

a substrate, and two or more lasing media arranged on the substrate, each lasing medium emitted electromagnetic radiation at one of the plurality of different wavelengths,

a detector that detects affected electromagnetic radiation resulting from the emitted electromagnetic radiation affected by the liquid drug and provides output representing spectral information of the liquid drug spectrum at the wavelengths, and

a processor configured to identify or verify the liquid drug from the detector output by;

querying a database of reference liquid drugs and spectral information of the reference liquid drugs at the wavelengths, each reference liquid drug comprising a reference drug in a base liquid, the reference liquid drug having a reference liquid drug spectrum and the base liquid having a base liquid spectrum comprising at least one spectral characteristic feature between about 1300 nm and about 2000 nm, there being a difference between the base liquid spectrum and the reference liquid drug spectrum at the least one spectral characteristic feature that provides discrimination from other reference drugs at the at least one spectral characteristic feature, and

identifying or verifying the liquid drug using;

a) the liquid drug detector output representing the spectral information of the liquid drug, and b) the spectral information of the reference liquid drugs, wherein the discrimination between the reference drugs assists with identifying or verifying.

2. An analyser according to claim 1 wherein the integrated laser further comprises:

an optical modulator arranged on the substrate to modulate electromagnetic radiation in an output optical path.

3. An analyser according to claim 2 wherein the integrated laser further comprises a collimating lens that receives electromagnetic radiation from the output optical path and/or optical modulator and collimates it to emit the electromagnetic radiation at the liquid drug.

4. An analyser according to claim 2 further comprising an optical fibre that is coupled to the output optical path and/or optical modulator to emit the electromagnetic radiation at the liquid drug.

5. An analyser according to claim 4 wherein the integrated laser further comprises one or more monitor diodes arrange to detect the electromagnetic radiation on the output optical path, optical fibre and/or optical modulator to measure the output power of the lasing media.

6. An analyser according to claim 1 wherein the integrated laser further comprises one or more monitor diodes arranged to measure the output power of the lasing media.

7. An analyser according to claim 1 wherein the integrated laser further comprises an integrated thermo-electric cooling/heating device to control the temperature of the integrated laser.

8. An analyser according to claim 7 wherein the integrated thermoelectric cooling/heating device is a Peltier device and/or thermistor.

11. An analyser according to claim 1 wherein the integrated laser further comprises:

a multiple channel optical waveguide arranged on the substrate, each channel coupled to a laser output to carry the electromagnetic radiation emitted from the laser, and

an optical combiner for combining the multiple channel optical waveguide into one optical waveguide channel on the substrate to combine the electromagnetic radiation emitted from each lasing medium carried on each optical waveguide channel into a single combined electromagnetic radiation output in a single narrow output optical path.

9. A method for identifying or verifying a liquid drug comprising a drug in a base liquid, the liquid drug having a liquid drug spectrum and the base liquid having a base liquid spectrum comprising at least one spectral characteristic feature between about 1300 nm and about 2000 nm, comprising:

providing an integrated laser for emitting electromagnetic radiation at a liquid drug, the electromagnetic radiation comprising a plurality of different wavelengths spread across about 1300 nm to about 2000 nm, wherein at least one of the wavelengths is in the vicinity of or within a region spanning a wavelength of a spectral characteristic feature of the base liquid spectrum, the integrated laser comprising;

a substrate, and two or more lasing media arranged on the substrate, each lasing medium emitting electromagnetic radiation at one of the plurality of different wavelengths,

providing at least one detector for detecting affected electromagnetic radiation resulting from the emitted electromagnetic radiation affected by the liquid drug and provides output representing spectral information of the liquid drug spectrum at the wavelengths,

providing a processor configured to identify or verify the liquid drug from the detector output,

querying a database of reference liquid drugs and spectral information of the reference liquid drugs at the wavelengths, each reference liquid drug comprising a reference drug in a base liquid, the reference liquid sdrug having a reference liquid drug spectrum and the base liquid having a base liquid spectrum comprising at least one spectral characteristic feature between about 1300 nm and about 2000 nm, there being a difference between the base liquid spectrum and the reference liquid drug spectrum at the least one spectral characteristic feature that provides discrimination from other reference drugs at the at least one spectral characteristic feature, and

identifying or verifying the liquid drug using;

a) the liquid drug detector output representing the spectral information of the liquid drug, and b) the spectral information of the reference liquid drugs, wherein the discrimination between the reference drugs assists with identifying or verifying.

10. A method according to claim 9 wherein each lasing medium can be switched on, off or modulated by a suitable waveform, such as sinusoid, squarewave, or sawtooth.